Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Red Light Holland (TRIP) has received the first reports from studies of its natural psilocybin
  • The company has been working with Shaman Pharma Corp. and its cGMP laboratory partner CCrest Laboratories
  • The report demonstrated that Red Light’s truffles are a viable source of active compounds
  • With the first phase considered a success, the companies are wrapping up this work and moving to the next phases
  • Red Light Holland is an Ontario-based corporation engaged in the production, growth, and sale of a premium brand of magic truffles
  • Shares in Red Light Holland Corp. (TRIP) are steady, trading at $0.185 per share

Red Light Holland (TRIP) has received the first reports for its natural psilocybin from its Health Canada approved laboratory partners.

The company has been working with Shaman Pharma Corp. and its cGMP laboratory partner CCrest Laboratories to evaluate the naturally occurring psilocybin as a source of active pharmaceutical ingredients (API).

After receiving Health Canada approval to export its truffles, Red Light Holland shipped the truffles from its farm in the Netherlands to CCrest’s pharmaceutical laboratory in Montreal.

The study will provide Red Light Holland customers with scientific information regarding the relative strength of the company’s various strains of truffles.

Todd Shapiro, CEO and director of Red Light Holland, commented on the partnership.

“This report is a step forward both for the recreational market, as well as the pharmaceutical market interested in naturally occurring psilocybin,” he said. “Red Light Holland and Shaman Pharma are once again pushing the limits, having a true ally and partner with cutting-edge scientific expertise to evaluate our truffles.”

Given the prohibited status of psilocybin, listed along with Schedule I drugs under the United Nations 1971 Convention on Psychotropic Substances, science on the subject has remained limited.

The recent report demonstrated that Red Light’s truffles are a viable source of active compounds, and the next objective is using the compounds in the development process of pharma-grade ingredients or creating standardized doses for legal markets.

With the first phase considered a success, the companies are wrapping up this work and moving to the next phases.

“We are advancing in uncharted territory where we are discovering a promising horizon, so we are definitely motivated to keep moving forward,” said Alex Grenier, CEO of Shaman Pharma and President of CCrest Laboratories.

Red Light Holland is an Ontario-based corporation engaged in the production, growth, and sale of a premium brand of magic truffles.

Shares in Red Light Holland Corp. (TRIP) are steady, trading at $0.185 per share as of 11:27 am ET.

More From The Market Herald
Red Light Holland - Director and CEO, Todd Shapiro (right).

" Red Light Holland (CSE:TRIP) expands footprint in Q2

Red Light Holland (TRIP) has reported Q2 results highlighted by a 64-per-cent increase in gross profit from Q1.

" Psyence Group (CSE:PSYG) to speak at the annual Global Wellness Summit

Psyence Group (PSYG) will break new ground as the first psychedelic company invited to speak at the 15th Annual Global Wellness Summit.
The Market Herald Video

" Algernon (CSE:AGN) announces positive feedback on its planned Phase 1/2a DMT Human Stroke Study

Algernon (AGN) received positive feedback at a scientific advice meeting from the United Kingdom Medicines and Healthcare Products Regulatory Agency.